Post-COVID Heart Syndrome; Auto-Antibodies in COVID Clotting; CT Training

Covid-19, News

Screening echo and cardiac MRI (CMR) turned up abnormal in 56% of 54 consecutive collegiate athletes recovering from COVID-19, with resolving pericardial inflammation in 39%. None had imaging suggestive of myocarditis. (JACC: Cardiovascular Imaging)

The RECOVERY trial, which brought us dexamethasone for COVID-19, is adding an aspirin arm for 2,000 people hospitalized with the virus to see if it improves survival. The NIH ACTIV-4 trial also is studying aspirin, but for newly-diagnosed ambulatory cases.

More than half of patients hospitalized with COVID-19 were at least transiently positive for antiphospholipid antibodies, which accelerated venous thrombosis in mice. (Science Translational Medicine)

Those autoantibodies prevalent in COVID-19 hospitalized patients were linked to thrombosis in a meta-analysis published as a preprint.

Stroke with COVID-19 was disproportionately seen in Asian people living in Britain. (Daily Mail)

In abstracts and full papers released ahead of the virtual American Heart Association meeting, researchers reported:

  • After acute MI, a 90-day window on readmissions might be better than the typical 30 days
  • With shorter admissions for transcatheter aortic valve replacement (TAVR), more people are having to come back for a second admission to get a pacemaker afterward (JACC: Cardiovascular Interventions)
  • The proportion of women with hypertension before pregnancy has nearly doubled in the past decade (JACC)
  • Comorbid cardiac amyloidosis and severe aortic stenosis had worse clinical presentation and a trend toward poorer outcomes, although TAVR appeared equally effective as in those without cardiac amyloidosis (JACC)

Stroke is the most burdensome neurologic disorder in the U.S. (JAMA Neurology)

Vascular News said Shockwave’s intravascular lithotripsy beat percutaneous transluminal angioplasty for procedural success in calcified superficial femoral and popliteal lesions in the Disrupt PAD III trial reported at the virtual VIVA conference. A summary of the other late-breaking clinical trials at the conference is here.

Clopidogrel (Plavix) use made no difference to the advantage of adding rivaroxaban (Xarelto) to aspirin in peripheral arterial disease in analysis of the VOYAGER PAD trial. (Circulation)

The Society of Cardiovascular Computed Tomography released guidelines on training.

Last Updated November 10, 2020

Articles You May Like

How can sugar affect our mental health?
Small portion of COVID-19 patients infectious long-term
Ublituximab Improves Functional MS Score: New ULTIMATE Analysis
Community Comes Together To Give Terminally Ill Father One Last Christmas Surprise
No Advantages to Using ADM in Implant-Based Breast Reconstruction

Leave a Reply

Your email address will not be published. Required fields are marked *